Advertisement

Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience

Abstract

Aims. The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown.
Methods and study design. Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated.
Results. Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity.
Conclusions. Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.

Tumori 2014; 100(6): 605 - 611

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1778.19260

Authors

Paolo Carli, Loredana Militello, Gian Maria Miolo, Daniela Quitadamo, Davide Lombardi, Elena Torrisi, Simona Scalone, Diana Crivellari, Simon Spazzapan

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Carli, Paolo [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Militello, Loredana [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Miolo, Gian Maria [PubMed] [Google Scholar]
    Division of Medical Oncology B, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Quitadamo, Daniela [PubMed] [Google Scholar]
    Scientific Directorate, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Lombardi, Davide [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Torrisi, Elena [PubMed] [Google Scholar]
    Catania University, Catania, Italy
  • Scalone, Simona [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Crivellari, Diana [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy
  • Spazzapan, Simon [PubMed] [Google Scholar]
    Division of Medical Oncology C, National Cancer Institute-IRCCS, Aviano (PN), Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.